Novavax to Participate in Fireside Chat at Devex @ UNGA 76
Novavax (Nasdaq: NVAX) announced that John J. Trizzino, Executive Vice President, will participate in a fireside chat at Devex @ UNGA 76 on September 21, 2021, at 8:50 a.m. The discussion will focus on the status of Novavax' COVID-19 vaccine candidate, NVX-CoV2373, and initiatives for global vaccine access. The event runs from September 21-23 and will be livestreamed. Novavax is known for its innovative vaccine solutions aimed at serious infectious diseases.
- None.
- None.
GAITHERSBURG, Md., Sept. 20, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing and commercializing next-generation vaccines for serious infectious diseases, today announced that John J. Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer, will be interviewed at Devex @ UNGA 76 on September 21 at 8:50 a.m. The event is hosted by the media outlet Devex and is taking place September 21-23 via livestream as part of its coverage of the 76th meeting of the United Nations General Assembly (UNGA 76). Novavax' COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion along with fostering global vaccine access.
Interview details are as follows:
Date: | Tuesday, September 21, 2021 |
Time: | 8:50 - 9:05 a.m. |
Location: | |
Title: | Fireside chat: A status report on the COVID-19 vaccine rollout |
Novavax panelist: | John J. Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer |
Moderator: | Jenny Lei Ravelo, Senior Reporter, Devex |
For more information or to register for the fireside chat, visit:
https://pages.devex.com/devex-at-unga-76.html
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.
Contacts:
Investors
Novavax, Inc.
Erika Schultz | 240-268-2022
ir@novavax.com
Solebury Trout
Alexandra Roy | 617-221-9197
aroy@soleburytrout.com
Media
Alison Chartan | 240-720-7804
Laura Keenan | 202-709-7521
media@novavax.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-participate-in-fireside-chat-at-devex--unga-76-301380800.html
SOURCE Novavax, Inc.
FAQ
What is the date of Novavax's participation in the UNGA 76 event?
Who from Novavax will speak at the fireside chat?
What will be discussed during the Novavax interview at UNGA 76?
When is the fireside chat featuring Novavax?
How can I access the Novavax interview at UNGA 76?
